150 related articles for article (PubMed ID: 38026075)
1. A study comparing baseline and best-corrected visual acuity after iodine-125 episcleral brachytherapy in uveal melanoma.
Miguel D; de Frutos JM; Alonso P; García-Álvarez C; Saornil MA; Diezhandino P; Garavis MI; Valencia P
J Contemp Brachytherapy; 2023 Oct; 15(5):350-356. PubMed ID: 38026075
[TBL] [Abstract][Full Text] [Related]
2. Vision Loss Following Episcleral Brachytherapy for Uveal Melanoma: Development of a Vision Prognostication Tool.
Aziz HA; Singh N; Bena J; Wilkinson A; Singh AD
JAMA Ophthalmol; 2016 Jun; 134(6):615-20. PubMed ID: 27101414
[TBL] [Abstract][Full Text] [Related]
3. Visual outcome after posterior uveal melanoma episcleral brachytherapy including radiobiological doses.
Miguel D; de Frutos-Baraja JM; López-Lara F; Antonia Saornil M; García-Alvarez C; Alonso P; Diezhandino P
J Contemp Brachytherapy; 2018 Apr; 10(2):123-131. PubMed ID: 29789761
[TBL] [Abstract][Full Text] [Related]
4. Long-term results of visual function in posterior uveal melanoma patients treated with I125 episcleral brachytherapy in a Spanish referral Ocular Oncology Unit.
Vicente N; Saornil MA; Almaraz A; Muñoz-Moreno MF
Arq Bras Oftalmol; 2021; 84(4):330-338. PubMed ID: 33567036
[TBL] [Abstract][Full Text] [Related]
5. Long-term visual acuity outcomes in patients with uveal melanoma treated with 125I episcleral OSU-Nag plaque brachytherapy.
Wisely CE; Hadziahmetovic M; Reem RE; Hade EM; Nag S; Davidorf FH; Martin D; Cebulla CM
Brachytherapy; 2016; 15(1):12-22. PubMed ID: 26525215
[TBL] [Abstract][Full Text] [Related]
6. Repeat Episcleral Plaque Brachytherapy: Clinical Outcomes in Patients Treated for Locally Recurrent Posterior Uveal Melanoma.
King B; Morales-Tirado VM; Wynn HG; Gao BT; Ballo MT; Wilson MW
Am J Ophthalmol; 2017 Apr; 176():40-45. PubMed ID: 28048976
[TBL] [Abstract][Full Text] [Related]
7. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16.
Melia BM; Abramson DH; Albert DM; Boldt HC; Earle JD; Hanson WF; Montague P; Moy CS; Schachat AP; Simpson ER; Straatsma BR; Vine AK; Weingeist TA;
Ophthalmology; 2001 Feb; 108(2):348-66. PubMed ID: 11158813
[TBL] [Abstract][Full Text] [Related]
8. Pattern of Local Recurrence After I-125 Episcleral Brachytherapy for Uveal Melanoma in a Spanish Referral Ocular Oncology Unit.
Sánchez-Tabernero S; García-Alvarez C; Muñoz-Moreno MF; Diezhandino P; Alonso-Martínez P; de Frutos-Baraja JM; López-Lara F; Saornil MA
Am J Ophthalmol; 2017 Aug; 180():39-45. PubMed ID: 28572063
[TBL] [Abstract][Full Text] [Related]
9. Temporal Evolution and Dose-Volume Histogram Predictors of Visual Acuity After Proton Beam Radiation Therapy of Uveal Melanoma.
Polishchuk AL; Mishra KK; Weinberg V; Daftari IK; Nguyen JM; Cole TB; Quivey JM; Phillips TL; Char DH
Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):91-97. PubMed ID: 27838186
[TBL] [Abstract][Full Text] [Related]
10. Endoresection with adjuvant ruthenium brachytherapy for selected uveal melanoma patients - the Tuebingen experience.
Süsskind D; Dürr C; Paulsen F; Kaulich T; Bartz-Schmidt KU
Acta Ophthalmol; 2017 Dec; 95(8):e727-e733. PubMed ID: 27914117
[TBL] [Abstract][Full Text] [Related]
11. Small choroidal melanoma: outcomes following apical height dose brachytherapy.
Yupari RJ; Bena J; Wilkinson A; Suh J; Singh A
Br J Ophthalmol; 2021 Aug; 105(8):1161-1165. PubMed ID: 32878827
[TBL] [Abstract][Full Text] [Related]
12. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
Bergman L; Nilsson B; Lundell G; Lundell M; Seregard S
Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063
[TBL] [Abstract][Full Text] [Related]
13. Pigmented episcleral deposits after brachytherapy of uveal melanoma.
Toivonen P; Kivelä T
Ophthalmology; 2006 May; 113(5):865-73. PubMed ID: 16530837
[TBL] [Abstract][Full Text] [Related]
14. Visual acuity, oncologic, and toxicity outcomes with
Patel KR; Prabhu RS; Switchenko JM; Chowdhary M; Craven C; Mendoza P; Danish H; Grossniklaus HE; Aaberg TM; Aaberg T; Reddy S; Butker E; Bergstrom C; Crocker IR
Brachytherapy; 2017; 16(3):646-653. PubMed ID: 28262517
[TBL] [Abstract][Full Text] [Related]
15. Retina dose as a predictor for visual acuity loss in
Heilemann G; Fetty L; Blaickner M; Nesvacil N; Zehetmayer M; Georg D; Dunavoelgyi R
Radiother Oncol; 2018 Jun; 127(3):379-384. PubMed ID: 29452902
[TBL] [Abstract][Full Text] [Related]
16. Outcomes for posterior uveal melanoma: Validation of American Brachytherapy Society Guidelines.
Meidenbauer K; Richards Z; Yupari RJ; Bena JF; Wilkinson A; Suh J; Singh AD
Brachytherapy; 2021; 20(6):1226-1234. PubMed ID: 34305017
[TBL] [Abstract][Full Text] [Related]
17. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients.
Shields CL; Shields JA; Cater J; Gündüz K; Miyamoto C; Micaily B; Brady LW
Arch Ophthalmol; 2000 Sep; 118(9):1219-28. PubMed ID: 10980767
[TBL] [Abstract][Full Text] [Related]
18. Iodine-I25 episcleral plaque therapy in uveal melanoma.
Sia S; Harper C; McAllister I; Perry A
Clin Exp Ophthalmol; 2000 Dec; 28(6):409-13. PubMed ID: 11202462
[TBL] [Abstract][Full Text] [Related]
19. Incidence of cataract and outcomes after cataract surgery in the first 5 years after iodine 125 brachytherapy in the Collaborative Ocular Melanoma Study: COMS Report No. 27.
Collaborative Ocular Melanoma Study Group
Ophthalmology; 2007 Jul; 114(7):1363-71. PubMed ID: 17337065
[TBL] [Abstract][Full Text] [Related]
20. Early outcomes of uveal melanoma treated with intraoperative ultrasound guided brachytherapy using custom built plaques.
Tann AW; Teh BS; Scarboro SB; Lewis GD; Bretana ME; Croft PC; Raizen Y; Butler EB; Kim RS; Chevez-Barrios P; Schefler AC
Pract Radiat Oncol; 2017; 7(4):e275-e282. PubMed ID: 28377140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
